Cabaletta Bio에 대한 매도 수량은 투자자에게 Cabaletta Bio의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Cabaletta Bio (NASDAQ:CABA) 주식, 공매도 수량 보고

Cabaletta Bio

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.

Equities

Markets

CABA

카발레타 바이오(NASDAQ:CABA)의 주가는 수요일 24.38% 상승한 3.01달러에 마감했으며, 전신 경화증(Systemic Sclerosis) 약물 시험 업데이트 이후 시간외 거래에서 4.65% 상승한 주당 3.15달러에 거래되었다.

카발레타 바이오, 전신 경화증 약물 시험 업데이트 이후 수요일 23개월 만에 최대 급등

Cabaletta Bio Inc

Cabana Target Beta ETF

Cabana Target Drawdown 10 ETF

Cabana Target Leading Sector Moderate ETF

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/10063817/Maoyan.jpeg" alt="" class="wp-image-7452" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/10063817/Maoyan.jpeg 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/10063817/Maoyan-300x200.jpeg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/10063817/Maoyan-768x512.jpeg 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The movie ticketing platform was dragged down by a 23% decline in China's box office last year, but held out hope for a stronger 2025
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul>
<li>Maoyan said its profit fell by more than 80% in 2024 on a weak performance at China's box office</li>
<li>The movie ticket seller has gotten off to a strong start this year as it benefits from the record box office for animated blockbuster ‘Ne Zha 2'</li>
</ul>
China's box office got a bounce post-pandemic from people eager to return to theaters, many of which were previously shut or operated on a limited basis to keep Covid-19 in check. But that bounce has faded lately as life returns to normal. A weak economy isn't helping matters either, causing China's box office to shrink by more than 20% last year as people reined in their spending on non-essential items like movie viewing.
The gloom cast a shadow over leading online movie ticketing platform&nbsp;Maoyan Entertainment&nbsp;(1896.HK) last year, causing its business to sag. Late last month, the company&nbsp;<a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0227/2025022700893.pdf">warned that</a>&nbsp;its revenue last year fell around 14% to between 4.05 billion yuan ($560 million) and 4.15 billion yuan, as its profit plummeted around 80% to between 150 million yuan and 200 million yuan. Despite that gloom, it held out hope for better times this year on a strong performance for the Chinese box office over the recent Lunar New Year holiday.
<h4 class="wp-block-heading">Slumping box office</h4>
Maoyan attributed the profit decline mainly to the drop in China's box office last year. The number of moviegoers also fell 22.3% year-on-year to 1.01 billion viewings. The situation was especially grim in the second half of the year, when the box office plunged 35.1% year-on-year, sending a chill through Maoyan's core movie ticketing business.
As a movie investor, Maoyan also took a hit from poor performance for some of its productions, leading to a substantial decline in profits from its content services business.
One bright spot for the company was the live entertainment market, which managed to grow in 2024 to historic highs. But revenue related to that business is relatively small for Maoyan, with movie production and ticket sales much larger, leading to the company's sharp profit decline.
Despite the grim year, Maoyan was quite optimistic about 2025. It pointed out that China's national box office exceeded 22.2 billion yuan as of Feb. 26, with new records set during the important Chinese New Year holiday season. It said "Detective Chinatown 1900," for which it was the lead distributor and producer, was the second highest gross film during the period, taking in more than 3.3 billion yuan.
Furthermore, it said some of the other films it helped to produce or distribute, including "Endless Journey of Love," have been scheduled, while "The Litchee Road," "De Xian Jin Zhi," "The Dumpling Queen" and many others are steadily progressing for release at the right time.
Maoyan's bullish eye on this year owes largely to the strong Chinese New Year box office performance, which was mainly attributable to the blockbuster animated film "Ne Zha 2." Not only did the film become China's top-grossing movie, but it also entered the global box office top 10 and became the highest-grossing animated movie of all time. Its box office already exceeds 14 billion yuan, equivalent to one-third of the Chinese box office in 2024.
<h4 class="wp-block-heading">Serendipitous success</h4>
Maoyan commands a majority 60% China's online ticketing market, which means the company automatically benefits from a higher box office. But whether the box office can continue its strong year as "Ne Zha 2" inevitably fades remains an open question. It's hardly guaranteed that more blockbusters will emerge this year. Moreover, an element of serendipity in the unprecedented popularity of "Ne Zha 2" won't be easy to replicate.
On a broader time horizon, China's box office has gradually returned to normal in the post-pandemic era. It plunged during the pandemic, falling from 47 billion yuan in 2021 to just 30 billion yuan at the peak in 2022, before bouncing back to 55 billion yuan in 2023 with the end of restrictions. But then it slipped again to 42.5 billion yuan in 2024 as the rebound ran out of fuel. Generally speaking, the annual figure should normally fall between 40 billion yuan and 50 billion yuan, meaning Maoyan, as the largest online ticket seller, is unlikely to achieve any major breakthrough as long as it stays in that range.
Maoyan's other major revenue source, movie distribution and production, also depends on hit movies, which is beyond its control. In that regard it's certainly not alone, as even Hollywood has yet to figure out a guaranteed formula that can spell the difference between success and failure for a movie.
<h4 class="wp-block-heading">Viewing blues</h4>
China's sluggish economy is the most important factor in the current environment, making people naturally more cautious with their money. Even though movie tickets are relatively cheap, it's even cheaper to watch them online not long after their theatrical releases, and cautious consumers may be happy to wait to save some money. That bodes poorly for companies like Maoyan over the longer term, despite the strong start to 2025.
Maoyan's stock currently trades at a price-to-earnings (P/E) ratio of about 9 times. We can ignore comparisons to its major shareholder, "Ne Zha 2" creator&nbsp;Enlight Media&nbsp;(300251), whose ratio has skyrocketed to 140 times on the success of its huge hit. In fact, Maoyan's actual ratio is probably a bit higher than 9 times, based on its latest profit guidance, which would place it at 30 to 40 times. But such movie-related stocks may be shunned by long-term investors put off by their unpredictability.
"The one that shapes my destiny will always be myself rather than the God," the heroine in "Ne Zha" utters at one point in the movie. But piloting their own destinies may be difficult for movie-related companies like Maoyan, whose fate can hinge on just one or two successes or box office flops.

Asia

Entertainment

Struggling Maoyan Gets a Boost In 2025 From 'Ne Zha 2'

Jefferies analyst Linda Tsai upgrades Camden Prop Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPT#NYSE">CPT</a>) from Hold to Buy and raises the price target from $117 to $139.

News

Upgrades

Price Target

Analyst Ratings

Jefferies Upgrades Camden Prop Trust to Buy, Raises Price Target to $139

The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Target Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>)</h3>
<ul>
<li>On March 4, the company reported a fourth-quarter sales decline of 3.1% year-on-year to $30.91 billion, beating the analyst consensus estimate of $30.84 billion. "Our team grew traffic and delivered better-than-expected sales and profitability in our biggest quarter of the year," said chair and chief executive officer Brian Cornell. The company's stock fell around 12% over the past month and has a <a href="https://www.benzinga.com/quote/TGT">52-week low of $112.10</a>.</li>
<li>RSI Value: 29</li>
<li>TGT Price Action: Shares of Target gained 0.9% to close at $115.08 on Friday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest TGT <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent031025&amp;t=be2bearmibe3na1">news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent031025&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="902" height="828" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/09102905/image-39.png" alt="" class="wp-image-815446" style="width:592px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/09102905/image-39.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/09102905/image-39-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/09102905/image-39-768x705.png 768w" sizes="(max-width: 902px) 100vw, 902px" /></a></figure>
<h3 class="wp-block-heading">Eastside Distilling Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLNE#NASDAQ">BLNE</a>)</h3>
<ul>
<li>On Feb. 19, Eastside Distilling closed a $5 million private placement. Over half of the capital came from Nick Liuzza, the founder and CEO of Beeline Financial Holdings, who invested $2.9 million.. The company's stock fell around 2% over the past five days and <a href="https://www.benzinga.com/quote/BLNE">has a 52-week low</a> of $0.41.</li>
<li>RSI Value: 19.1</li>
<li>BLNE Price Action: Shares of Eastside Distilling gained 1.2% to close at $0.75 on Friday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent031025&amp;t=be2bearmibe3na1">BLNE stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent031025&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="916" height="842" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/09102956/image-40.png" alt="" class="wp-image-815447" style="width:541px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/09102956/image-40.png 916w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/09102956/image-40-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/09102956/image-40-768x706.png 768w" sizes="(max-width: 916px) 100vw, 916px" /></a></figure>
<h3 class="wp-block-heading">Zevia Pbc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZVIA#NYSE">ZVIA</a>)</h3>
<ul>
<li>On Feb. 26, Zevia issued FY25 revenue guidance below estimates. &#8220;We are pleased to have ended the year on a strong note with a return to top line growth and significant progress towards achieving profitability. We elevated our brand identity, advanced our three strategic growth pillars and continued to lay a strong foundation for growth and profitability over the long term.&#8221; said Amy Taylor, President and Chief Executive Officer of Zevia. The company's stock fell around 37% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/ZVIA">low of $0.62.</a></li>
<li>RSI Value: 27.5</li>
<li>ZVIA Price Action: Shares of Zevia fell 2.7% to close at $2.17 on Friday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent031025&amp;t=be2bearmibe3na1">breakout in ZVIA shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent031025&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="871" height="846" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/09103132/image-41.png" alt="" class="wp-image-815448" style="width:515px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/09103132/image-41.png 871w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/09103132/image-41-300x291.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/09103132/image-41-768x746.png 768w" sizes="(max-width: 871px) 100vw, 871px" /></a></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/03/44187903/top-2-consumer-stocks-that-could-blast-off-this-quarter">Top 2 Consumer Stocks That Could Blast Off This Quarter</a></li>
</ul>

Long Ideas

Pre-Market Outlook

Trading Ideas

BLNE

ZVIA

Top 3 Defensive Stocks That Are Preparing To Pump This Month

Shares of Checkpoint Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CKPT#NASDAQ">CKPT</a>) rose sharply in today's <a href="https://www.benzinga.com/quote/CKPT/news">pre-market trading</a>.
Sun Pharma announced plans to acquire Checkpoint Therapeutics in a $355 million deal.
Checkpoint Therapeutics shares jumped 66% to $4.10 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>AtlasClear Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATCH#NYSE">ATCH</a>) rose 79.9% to $2.50 in pre-market trading after falling 12% on Friday.</li>
<li>Sharps Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) gained 63.9% to $0.4863 in pre-market trading after gaining more than 12% on Friday.</li>
<li>Icon Energy Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICON#NASDAQ">ICON</a>) gained 37.1% to $0.2315 in pre-market trading after jumping 16% on Friday.</li>
<li>Trevi Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVI#NASDAQ">TRVI</a>) gained 25.4% to $5.39 in pre-market trading after reporting topline results from its Phase 2a RIVER trial of Haduvio For the treatment of patients with RCC (N=66).</li>
<li>Sonoma Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNOA#NASDAQ">SNOA</a>) gained 19% to $2.38 in pre-market after dipping 8% on Friday.</li>
<li>NET Power Inc.  (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NPWR#NYSE">NPWR</a>) rose 16.4% to $8.07 after gaining 7% on Friday.</li>
<li>Veren Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRN#NYSE">VRN</a>) gained 14.1% to $5.60 in pre-market trading. Whitecap Resources and Veren announced plans to combine in a $15 billion transaction to create a leading Canadian light oil and condensate producer.</li>
<li>Mineralys Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLYS#NASDAQ">MLYS</a>) shares climbed 13.3% to $11.92 in pre-market trading after the company said it will announce topline data from its LAUNCH-HTN and ADVANCE-HTN trials on March 10.</li>
<li>Exodus Movement, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXOD#NYSE">EXOD</a>) gained 6.8% to $31.39 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Able View Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABLV#NASDAQ">ABLV</a>) shares fell 26.4% to $1.28 in pre-market trading after jumping 129% on Friday.</li>
<li>SUNation Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUNE#NASDAQ">SUNE</a>) dipped 18.2% to $0.3261 in pre-market trading after surging 125% on Friday.</li>
<li>Advanced Biomed Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADVB#NASDAQ">ADVB</a>) declined 17% to $3.03 in pre-market trading. Advanced Biomed announced the closing of $6.56 million initial public offering.</li>
<li>Starbox Group Holdings Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STBX#NASDAQ">STBX</a>) shares fell 15.4% to $0.33 in pre-market trading after jumping 7% on Friday.</li>
<li>Kazia Therapeutics Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZIA#NASDAQ">KZIA</a>) fell 15.3% to $1.00 in today's pre-market trading after jumping 40% on Friday.</li>
<li>Plus Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) fell 13.4% to $1.36 in pre-market trading after gaining 9% on Friday.</li>
<li>Twin Vee Powercats Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEEE#NASDAQ">VEEE</a>) shares tumbled 11.8% to $0.35 in pre-market trading.</li>
<li>Phoenix Motor Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEV#NASDAQ">PEV</a>) fell 9.2% to $0.2965 in pre-market trading. Phoenix Motor said it projected 2024 revenue of $30 million-$31 million, up from $3 million in 2023.</li>
<li>Intuitive Machines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) shares dipped 9.2% to $7.95 in pre-market trading. Intuitive Machines shares dipped 22% on Friday after the company&#8217;s lander experienced technical issues.</li>
<li>Robinhood Markets, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) fell 6.3% to $41.58 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/03/44187903/top-2-consumer-stocks-that-could-blast-off-this-quarter">Top 2 Consumer Stocks That Could Blast Off This Quarter</a></li>
</ul>

ABLV

ADVB

ATCH

CKPT

EXOD

HOOD

ICON

KZIA

LUNR

MLYS

NPWR

PSTV

SNOA

STBX

STSS

SUNE

TRVI

VEEE

Why Checkpoint Therapeutics Shares Are Trading Higher By Around 66%; Here Are 20 Stocks Moving Premarket

Compass Point analyst Floris Van Dijkum downgrades Host Hotels &amp; Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HST#NASDAQ">HST</a>) from Buy to Neutral and lowers the price target from $20 to $18.

Downgrades

Compass Point Downgrades Host Hotels & Resorts to Neutral, Lowers Price Target to $18

Compass Point analyst Floris Van Dijkum downgrades Pebblebrook Hotel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEB#NYSE">PEB</a>) from Buy to Neutral.

Compass Point Downgrades Pebblebrook Hotel to Neutral

This updated guidance reflects the Company's continued momentum in the second quarter of fiscal 2025 for its core U.S. Healthcare Solutions reportable segment and does not reflect any change in expectations for its recently completed acquisition of Retina Consultants of America.

Earnings

Guidance

Health Care

General

Cencora Expects 2025 Adjusted EPS Of $15.30-$15.60, Up From The Previous Range Of $15.25-$15.55 Compared To Consensus Of $16.82-8K

Jefferies analyst John Colantuoni upgrades Airbnb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) from Hold to Buy and raises the price target from $165 to $185.

ABNB

Jefferies Upgrades Airbnb to Buy, Raises Price Target to $185

Gary Black has highlighted a ‘misinterpretation' by the media regarding Tesla Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) first-quarter delivery shortfall.
As per the Tesla bull, reports have attributed Elon Musk&#8216;s political comments and DOGE spending cutbacks, but Black points to a different cause.
What Happened: In a social media post on X, Black said the actual reason for the delivery shortfall is that buyers are delaying their <a href="https://www.benzinga.com/tech/25/01/42905406/tesla-launches-refreshed-model-y-in-china-amid-rising-competition">Model Y</a> purchases until the refreshed version is launched.
While some Democrats may be less inclined to buy Teslas due to Musk&#8217;s political stance, Black suggests that Republicans might appreciate Musk&#8217;s statements and his involvement with DOGE.
This perspective challenges the narrative that political factors are the main reason for the delivery delays.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Many in the media are starting to recognize the shortfall in <a href="https://twitter.com/search?q=%24TSLA&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$TSLA</a> 1Q delivs is due in large part to buyers delaying taking deliveries of Model Y until the refreshed version is available. The naive media keeps blaming the 1Q delivery shortfall on Elon's political comments and… <a href="https://t.co/zhq9S6TONj">pic.twitter.com/zhq9S6TONj</a>
&mdash; Gary Black (@garyblack00) <a href="https://twitter.com/garyblack00/status/1898098447011475660?ref_src=twsrc%5Etfw">March 7, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Black&#8217;s post suggests that the media&#8217;s focus on Musk&#8217;s political activities may overlook other significant factors affecting Tesla&#8217;s sales performance. As the refreshed Model Y becomes available, it could potentially shift the delivery numbers in future quarters.
Why It Matters: The delivery shortfall comes at a time when Tesla&#8217;s sales have been under scrutiny. In September 2024, Gene Munster, a tech venture capitalist, noted that Tesla might report a<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41082647/tesla-could-report-slight-q3-deliveries-miss-amid-musks-political-controversies-mun"> slight miss</a> in Q3 deliveries due to Musk&#8217;s political controversies. Despite this, Munster remained optimistic about Tesla&#8217;s growth potential.
In early 2025, Tesla&#8217;s sales in California dropped by 12%, raising questions about the impact of Musk&#8217;s political support for Donald Trump on <a href="https://www.benzinga.com/trading-ideas/25/02/43447273/tesla-sales-drop-12-in-california-is-elon-musks-support-for-donald-trump-hurting-ev-sales">EV sales</a>. Additionally, <a href="https://www.benzinga.com/25/01/43152718/tesla-to-have-a-choppy-first-half-owing-to-new-ev-policies-deliveries-and-margins-however-this-analyst-expect-over-20-upside-from-current-level-with-a-500-target-price">analysts</a> predicted a &#8220;choppy&#8221; first half for Tesla due to new EV policies and uncertainties in deliveries.
Tesla&#8217;s California sales hit a four-year low, with <a href="https://www.benzinga.com/25/02/43765071/teslas-california-sales-hit-four-year-low-amid-political-concerns-researcher-says-left-leaning-customers-are-turning-away-from-ev-giant">researchers</a> attributing this to Musk&#8217;s political actions. The ongoing political climate, including potential tariffs on Mexico, could further impact Tesla&#8217;s operations, as highlighted in a <a href="https://www.benzinga.com/25/03/44176616/trump-vs-musk-tesla-to-be-hurt-by-tariffs-on-mexico-despite-friendship">March 2025 report</a>.
Check out more of Benzinga's Future Of Mobility coverage by <a href="https://www.benzinga.com/topic/mobility">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44213295/tesla-suspected-of-ev-rebate-manipulation-in-canada-amid-sudden-sales-surge-tesla-gamed-the-system-says-industry-body">Tesla Suspected Of EV Rebate Manipulation In Canada Amid Sudden Sales Surge Before Deadline: &#8216;Tesla Gamed The System&#8217;, Says Industry Body</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Tech

TSLA

Tesla Bull Says EV Giant's Q1 Delivery Shortfall Is Not Due To Elon Musk's Political Comments And DOGE: 'Republicans Are Likely Thrilled'

Management

YUMC

Yum China Holdings Names Adrian Ding As CFO, Effective March 6, 2025; Ding Has Been Serving As Acting CFO Since October 2024

Willis Lease Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLFC#NASDAQ">WLFC</a>) reported quarterly earnings of $2.81 per share which beat the analyst consensus estimate of $1.88 by 49.47 percent. This is a 83.66 percent increase over earnings of $1.53 per share from the same period last year. The company reported quarterly sales of $152.80 million which beat the analyst consensus estimate of $119.46 million by 27.90 percent. This is a 33.71 percent increase over sales of $114.28 million the same period last year.

Earnings Beats

WLFC

Willis Lease Finance Q4 2024 GAAP EPS $2.81 Beats $1.88 Estimate, Sales $152.80M Beat $119.46M Estimate

DRIO

DarioHealth FY 2024 GAAP EPS $0.61 Beats $(1.01) Estimate, Sales $27.040M Beat $26.821M Estimate

Electrical Products Group estimates revenues of approximately $375 million in the 12 months ending February 28, 2025, and has a strong backlog.
nVent expects the acquisition to be accretive to adjusted earnings per share in the first year following completion of the transaction. The effective enterprise value multiple is approximately 12.5 times the anticipated Electrical Products Group trailing twelve-month EBITDA. &nbsp;

nVent Electric Agrees To Acquire The Enclosures, Switchgear And Bus Systems Businesses Of Avail Infrastructure Solutions For $975M, Subject To Customary Adjustments

&nbsp;Today, Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to placebo. The trial included 1,206 randomised people with obesity or overweight and type 2 diabetes and a mean baseline body weight of 102 kg. &nbsp;The trial achieved its primary endpoint by demonstrating a statistically significant and superior weight loss at week 68 with CagriSema versus placebo. The REDEFINE 2 trial was based on a flexible protocol, allowing patients to modify their dosing throughout the trial. After 68 weeks, 61.9% of patients treated with CagriSema were on the highest dose. When evaluating the effects of treatment, if all people adhered to treatment1, people treated with CagriSema achieved a superior weight loss of 15.7% after 68 weeks compared to 3.1% with placebo. Weight loss of 5% or more after 68 weeks was a co-primary endpoint and was achieved by 89.7% of patients on CagriSema, compared to 30.3% by placebo. When applying the treatment policy estimand2, people treated with CagriSema achieved a superior weight loss of 13.7% compared to 3.4% with placebo. &nbsp;In the trial, CagriSema appeared to have a safe and well-tolerated profile. The most common adverse events with CagriSema were gastrointestinal, and the vast majority were mild to moderate and diminished over time, consistent with the GLP-1 receptor agonist class.&nbsp;

Novo Nordisk Reports Phase 3 Results for CagriSema, Showing 15.7% Weight Loss Over 68 Weeks

U.S. stocks settled higher on Friday, with the Dow Jones index gaining more than 200 points during the session. However, the index recorded losses last week.
The S&amp;P 500 recorded its worst week since September, falling 3.1% last week. The Dow declined 2.4%, while the Nasdaq Composite tumbled 3.5% during the week.
Wall Street analysts make new stock picks on a daily basis. Unfortunately for investors, not all analysts have particularly impressive track records at predicting market movements. Even when it comes to one single stock, analyst ratings and price targets can vary widely, leaving investors confused about which analyst&#8217;s opinion to trust.
Benzinga&#8217;s Analyst Ratings API is a collection of the highest-quality stock ratings curated by the Benzinga news desk via direct partnerships with major sell-side banks. Benzinga displays overnight ratings changes on a daily basis three hours prior to the U.S. equity market opening. Data specialists at investment dashboard provider Toggle.ai recently uncovered that the analyst insights Benzinga Pro subscribers and Benzinga readers regularly receive can successfully be used as trading indicators to outperform the stock market.
Top Analyst Picks: Fortunately, any Benzinga reader can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. One of the ways traders can sort through Benzinga&#8217;s extensive database of analyst ratings is by analyst accuracy. Here&#8217;s a look at the most recent stock picks from each of the five most accurate Wall Street analysts, according to Benzinga <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock</a> Ratings.
Analyst: Jay McCanless
<ul>
<li>Analyst Firm: Wedbush</li>
<li>Ratings Accuracy: 87%</li>
<li>Latest Rating: Reiterated an Outperform rating on Landsea Homes Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSEA#NASDAQ">LSEA</a>) with a price target of $15 on March 5. This analyst sees around 108% upside in the stock.</li>
<li>Recent News: On Feb. 27, the company posted record fourth quarter home sales revenue of $450.6 million.</li>
</ul>
Analyst: Lloyd Walmsley
<ul>
<li>Analyst Firm: UBS</li>
<li>Ratings Accuracy: 86%</li>
<li>Latest Rating: Maintained a Neutral rating on Opendoor Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPEN#NASDAQ">OPEN</a>) and cut the price target from $2 to $1.2 on March 4. This analyst sees around 2% decline in the stock.</li>
<li>Recent News: On Feb. 27, Opendoor Technologies posted upbeat fourth-quarter results.</li>
</ul>
Analyst: Trevor Walsh 
<ul>
<li>Analyst Firm: Citizens Capital Markets</li>
<li>Ratings Accuracy: 85%</li>
<li>Latest Rating: Reiterated a Market Outperform rating on CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) with a price target of $400 on March 5. This analyst sees around 20% upside in the stock.</li>
<li>Recent News: On March 4, CrowdStrike reported fourth-quarter revenue of $1.058 billion, beating the consensus estimate of $1.032 billion.</li>
</ul>
Analyst: Josh Sullivan
<ul>
<li>Analyst Firm: Benchmark</li>
<li>Ratings Accuracy: 85%</li>
<li>Latest Rating: Reiterated a Buy rating on BlackSky Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKSY#NASDAQ">BKSY</a>) with a price target of $17 on March 7. This analyst sees around 72% upside in the stock.</li>
<li>Recent News: On March 6, BlackSky Technology reported worse-than-expected fourth-quarter financial results.</li>
</ul>
Analyst: Zachary Fadem
<ul>
<li>Analyst Firm: Wells Fargo</li>
<li>Ratings Accuracy: 85%</li>
<li>Latest Rating: Maintained an Equal-Weight rating on Best Buy Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) and cut the price target from $89 to $85 on March 5. This analyst sees around 7% upside in the stock.</li>
<li>Recent News: On March 4, the company reported a fourth-quarter sales decline of 4.8% year-on-year to $13.948 billion, beating the analyst consensus estimate of $13.702 billion..</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/03/44187903/top-2-consumer-stocks-that-could-blast-off-this-quarter">Top 2 Consumer Stocks That Could Blast Off This Quarter</a></li>
</ul>

BlackSky Technology Inc. Class A Common Stock

BKSY

CRWD

LSEA

OPEN

This Analyst With 85% Accuracy Rate Sees More Than 20% Upside In CrowdStrike - Here Are 5 Stock Picks For Last Week From Wall Street's Most Accurate Analysts

Franco-Nevada Expect 2025 Revenue To Be Higher Over 25% YoY, Total GEO Sales Of 465,000 to 525,000 GEO

Franco-Nevada (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNV#NYSE">FNV</a>) reported quarterly earnings of $0.95 per share which beat the analyst consensus estimate of $0.89 by 6.74 percent. This is a 5.56 percent increase over earnings of $0.90 per share from the same period last year. The company reported quarterly sales of $321.00 million which beat the analyst consensus estimate of $305.85 million by 4.95 percent. This is a 5.84 percent increase over sales of $303.30 million the same period last year.

Franco-Nevada Q4 2024 Adj EPS $0.95 Beats $0.89 Estimate, Sales $321.00M Beat $305.85M Estimate

The establishment of a Strategic Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) Reserve and a Digital Asset Stockpile in the U.S. represents a new paradigm in the evolution of cryptocurrencies and one that could influence monetary policy in countries around the world.
While Bitcoin will have its own reserve, the Digital Asset Stockpile is expected to have Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>), XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>), Cardano (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ada/usd">ADA</a>), and Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>), according to <a href="https://www.benzinga.com/25/03/44068814/bitcoin-ethereum-dogecoin-rally-on-trumps-strategic-crypto-reserve-announcement-cardano-xrp-solana-skyrocket-analyst-says-btcs-new-ath-possible-later-in-the-month">Trump&#8217;s earlier announcement</a>.
The connecting thread among them all? They are the largest cryptocurrencies by market capitalization. In fact, excluding stablecoins, the reserve will contain five of the top six coins in terms of valuation.
But, if it was so obvious, the next logical question is why BNB Coin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/bnb/usd">BNB</a>), the fourth-largest cryptocurrency, was not included in the reserve.
Several analysts that Benzinga spoke to blamed it on the ‘China' angle.&nbsp;
<h2 class="wp-block-heading">Ties With An &#8216;Unfriendly&#8217; Trade Partner</h2>
"President Trump's decision to omit Binance Coin from the U.S. Crypto Reserve, despite its substantial market capitalization, may well have been influenced by the ongoing trade tensions between the U.S. and China, as Binance has strong ties to China," said Shant Kevonian, CEO and founder of Web3 email platform EtherMail.
It's worth noting that Binance was initially headquartered in China but moved out before the Chinese government <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40985461/china-controls-55-of-bitcoin-hashrate-despite-crypto-ban-but-the-us-is-catching-up">restricted cryptocurrency trading</a> in the country. As of this writing, the company has no official headquarters.
See Also:<a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39359780/dogecoin-shiba-inu-floki-are-dino-coins-says-trader-he-likes-these-3-other-meme-coins-as-b?itm_source=parsely-api"> </a><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44212481/dogecoin-plunges-9-but-top-analyst-believes-meme-coin-could-stage-a-strong-rebound-in-case-this-happens">Dogecoin Plunges 9% But Top Analyst Believes Meme Coin Could Stage A &#8216;Strong&#8217; Rebound In Case This Happens</a>
Kadan Stadelmann, blockchain developer and Chief Technology Officer of Komodo Platform, also emphasized the Chinese nationality of Yi He, the company's <a href="https://www.benzinga.com/markets/cryptocurrency/24/01/36468045/changpeng-zhao-is-out-but-yi-he-stays-inside-the-unseen-power-of-binances-co-founder">little-known co-founder</a>, apart from Changpeng "CZ" Zhao.
It's not news that Trump <a href="https://www.benzinga.com/25/03/44161587/is-china-apprehensive-of-losing-the-trade-war-to-the-us-china-could-get-isolated-like-moscow-fears-xi-jinping">champions an "America First"</a> policy, placing it at the center of his political rhetoric. He has spoken about putting the U.S. at the forefront of cryptocurrency innovation and avoiding ceding the space to China.
However, the China link wasn't the only cause for concern.
<h2 class="wp-block-heading">Is BNB CZ-Tainted?</h2>
"BNB was started and majority-owned by CZ—in fact, that&#8217;s how Binance funded itself for the 2017 ICO. CZ was recently jailed by the U.S. (Biden administration) for improper KYC, so there&#8217;s no way they&#8217;d include it in a strategic reserve," said Michael Terpin, CEO of Transform Ventures and author of the book Bitcoin Supercycle.
Indeed, CZ served a four-month prison sentence <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38547115/ex-binance-ceo-changpeng-zhao-sees-crypto-industry-entering-new-phase">for anti-money laundering violations</a>, paid a $50 million fine, and stepped down from the CEO's role.&nbsp;
Moreover, according to a Forbes <a href="https://www.forbes.com/sites/javierpaz/2024/06/14/how-cryptos-richest-billionaire-doubled-his-net-worth-behind-bars/">report</a>, he owns an estimated 94 million BNB tokens, roughly 64% of the total circulating supply.
Binance has yet to respond to Benzinga's request for comment on the exclusion from the reserve.
See Also:<a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39359780/dogecoin-shiba-inu-floki-are-dino-coins-says-trader-he-likes-these-3-other-meme-coins-as-b?itm_source=parsely-api"> </a><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44212481/dogecoin-plunges-9-but-top-analyst-believes-meme-coin-could-stage-a-strong-rebound-in-case-this-happens">Dogecoin Plunges 9% But Top Analyst Believes Meme Coin Could Stage A &#8216;Strong&#8217; Rebound In Case This Happens</a>
<h2 class="wp-block-heading">Litecoin&#8217;s Privacy: The Reason Behind Exclusion?</h2>
Another popular coin whose exclusion might have surprised some was Litecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ltc/usd">LTC</a>).&nbsp;
After all, the altcoin is <a href="https://www.benzinga.com/trading-ideas/movers/25/01/43047964/litecoin-surges-12-after-analyst-says-altcoin-most-likely-to-have-next-etf-after-bitcoin-ethereum">expected to be the next exchange-traded fund</a> on Wall Street after Bitcoin and Ethereum, with characteristics deemed "very" similar to the apex cryptocurrency.
So, what happened?
Stadelmann believes a privacy-friendly update executed by the Litecoin network in 2022 could be the reason.
"Perhaps Litecoin's 2022 MimbleWimble update, which allows for private transactions where only the sender and receiver know the details, gives Trump pause," Stadelmann told Benzinga.&nbsp;
Notably, the newly added privacy features created a storm, leading to <a href="https://upbit.com/service_center/notice?id=2714">delisting</a> from South Korean cryptocurrency exchanges over conflict with the country's reporting requirements.  
In its defense. Litecoin has stated that MimbleWimble is an <a href="https://www.benzinga.com/markets/cryptocurrency/20/10/17746253/maker-cardano-litecoin-american-wrap-1012020">optional feature</a>.
A spokesperson from the Litecoin Foundation backed LTC's inclusion in a U.S. cryptocurrency reserve and expressed optimism that things could change for the better.
"We are hopeful that thoughtful consideration is given to projects that can provide long-term value for a crypto reserve, and we are confident that if a crypto reserve is passed in Congress, that Litecoin would inevitably be added, given its similar characteristics to Bitcoin and value proposition."
Photo Courtesy: Matt Fowler KC on Shutterstock.com
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44212604/peter-schiff-establishes-personal-strategic-bitcoin-reserve-vows-not-to-sell-going-down-with-the-ship-so-others-never-get-on-board">Peter Schiff Establishes Personal &#8216;Strategic Bitcoin Reserve,&#8217; Vows Not To Sell: &#8216;Going Down With The Ship So Others Never Get On Board&#8217;</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Exclusives

$ADA

$BNB

$BTC

$ETH

$LTC

$SOL

$XRP

Trump Excluded Binance Coin And Litecoin From US Crypto Reserves,  Analysts Say China, CZ's Past And Privacy Concerns Behind The Move

Brown & Brown (Europe) Ltd. Acquires 100% Of The Share Capital Of Premier Commercial Ltd; Consideration Undisclosed

BECN

QXO And Beacon Roofing Supply Confirm Discussions About Potential Combination, In Which QXO Would Acquire Beacon For $124.35 Per Share In Cash, Or ~$11B

Press Releases

Cabaletta Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update

Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024

Cabaletta Bio to Participate in Upcoming Investor Conferences in December

Cabaletta Bio Outlines Strategic Priorities and Anticipated Key Milestones for 2025

Cabaletta Bio to Participate in Guggenheim's SMID Cap Biotech Conference

Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February

Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

Comments

Cabaletta Bio

매도 수량

Cabaletta Bio (NASDAQ:CABA) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌